Phase II trial of Linsitinib (anti-IGFR/IR) in patients with relapsed and/or refractory Ewing Sarcoma
Phase of Trial: Phase II
Latest Information Update: 10 Aug 2019
Price : $35 *
At a glance
- Drugs Linsitinib (Primary)
- Indications Ewing's sarcoma
- Focus Adverse reactions; Pharmacodynamics
- Acronyms LINES
- 21 Mar 2017 Status changed from active, no longer recruiting to completed.
- 11 Nov 2016 This trial has been completed in Netherlands.
- 19 May 2016 Status changed from recruiting to active, no longer recruiting.